Literature DB >> 21674184

Current evidence on the relationship between CYP1B1 polymorphisms and lung cancer risk: a meta-analysis.

Wenhuan Xu1, Yunhai Zhou, Xiaosheng Hang, Di Shen.   

Abstract

The association between single-nucleotide polymorphisms (SNPs) of the CYP1B1 gene and lung cancer risk is still ambiguous. In this meta analysis, we assessed 10 case-control studies included 7,067 cases and 9,374 controls of the association between CYP1B1 SNPs of Leu432Val (rs1056836, 432C>G), Asn453Ser (rs1800440, 453A>G), Ala119Ser (rs1056827, 119G>T), Arg48Gly (rs10012, 48C>G) and the risk of lung cancer. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to evaluate the strength of association between the polymorphism and lung cancer risk under codominant model, dominant model and additive model respectively. Although there were limitations, this meta analysis indicated that individuals with 432GG genotype had a 39.7% higher risk of having lung cancer than those with the 432CC genotype, and individuals with the 432G allele had a 26.3% increased risk as well. An increased risk of lung cancer of 2.13 fold was observed in individuals with 119TT genotype. For Arg48Gly, individuals with 48GG genotype had a significantly increased risk of lung cancer compared with individuals with 48CC (OR 3.859; 95% CI 2.536-5.87). Elevated risk of lung cancer were observed in dominant model (OR 2.115; 95% CI 1.653-2.705) as well. The risk of lung cancer was elevated as the frequency of G allele increased in additive model (P = 0.000). For individuals with the polymorphism at codon 453, no evidence of such association was observed. Furthermore, a possible association between the CYP1B1 polymorphism at codon 432 and the lung cancer could be detected in individuals of Caucasian origin, while a negative association was suggested in Asians and African-Americans. An increased lung cancer risk was also found in women with polymorphism at codon 453. These results are supportive for the hypothesis that the CYP1B1 432GG, 119TT and 48GG genotypes are low-penetrance risk factors for developing lung cancer, and further studies are needed to validate these associations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21674184     DOI: 10.1007/s11033-011-1041-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

1.  Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue.

Authors:  Y Ko; J Abel; V Harth; P Bröde; C Antony; S Donat; H P Fischer; M E Ortiz-Pallardo; R Thier; A Sachinidis; H Vetter; H M Bolt; C Herberhold; T Brüning
Journal:  Cancer Res       Date:  2001-06-01       Impact factor: 12.701

2.  Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer.

Authors:  J Watanabe; T Shimada; E M Gillam; T Ikuta; K Suemasu; Y Higashi; O Gotoh; K Kawajiri
Journal:  Pharmacogenetics       Date:  2000-02

Review 3.  The glutathione S-transferases: influence of polymorphism on cancer susceptibility.

Authors:  R C Strange; A A Fryer
Journal:  IARC Sci Publ       Date:  1999

4.  Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer.

Authors:  Mette Sørensen; Herman Autrup; Anne Tjønneland; Kim Overvad; Ole Raaschou-Nielsen
Journal:  Cancer Lett       Date:  2005-04-28       Impact factor: 8.679

5.  Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity.

Authors:  I H Hanna; S Dawling; N Roodi; F P Guengerich; F F Parl
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

6.  Impact of metabolic genotypes on levels of biomarkers of genotoxic exposure.

Authors:  B Schoket; G Papp; K Lévay; G Mracková; F F Kadlubar; I Vincze
Journal:  Mutat Res       Date:  2001-10-01       Impact factor: 2.433

7.  Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population.

Authors:  Geyu Liang; Yuepu Pu; Lihong Yin
Journal:  Cancer Lett       Date:  2005-06-08       Impact factor: 8.679

8.  Cytochrome P450 1B1 gene polymorphisms and postmenopausal breast cancer risk.

Authors:  Tove Rylander-Rudqvist; Sara Wedren; Fredrik Granath; Keith Humphreys; Susanne Ahlberg; Elisabete Weiderpass; Mikael Oscarson; Magnus Ingelman-Sundberg; Ingemar Persson
Journal:  Carcinogenesis       Date:  2003-07-04       Impact factor: 4.944

9.  CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences.

Authors:  Maria N Timofeeva; Silke Kropp; Wiebke Sauter; Lars Beckmann; Albert Rosenberger; Thomas Illig; Birgit Jäger; Kirstin Mittelstrass; Hendrik Dienemann; Helmut Bartsch; Heike Bickeböller; Jenny C Chang-Claude; Angela Risch; Heinz-Erich Wichmann
Journal:  Carcinogenesis       Date:  2009-05-04       Impact factor: 4.944

10.  A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers.

Authors:  Shanbeh Zienolddiny; Daniele Campa; Helge Lind; David Ryberg; Vidar Skaug; Lodve B Stangeland; Federico Canzian; Aage Haugen
Journal:  Carcinogenesis       Date:  2008-02-06       Impact factor: 4.944

View more
  13 in total

1.  Association between the CYP1B1 polymorphisms and risk of cancer: a meta-analysis.

Authors:  Jie-Ying Liu; Yu Yang; Zhi-Zhong Liu; Jian-Jun Xie; Ya-Ping Du; Wei Wang
Journal:  Mol Genet Genomics       Date:  2014-12-05       Impact factor: 3.291

2.  Toxicokinetics of benzo[a]pyrene in humans: Extensive metabolism as determined by UPLC-accelerator mass spectrometry following oral micro-dosing.

Authors:  Erin Madeen; Lisbeth K Siddens; Sandra Uesugi; Tammie McQuistan; Richard A Corley; Jordan Smith; Katrina M Waters; Susan C Tilton; Kim A Anderson; Ted Ognibene; Kenneth Turteltaub; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2018-12-21       Impact factor: 4.219

3.  Estrogen metabolism within the lung and its modulation by tobacco smoke.

Authors:  Jing Peng; Xia Xu; Brian E Mace; Lisa A Vanderveer; Laura R Workman; Michael J Slifker; Patrick M Sullivan; Timothy D Veenstra; Margie L Clapper
Journal:  Carcinogenesis       Date:  2012-12-31       Impact factor: 4.944

Review 4.  Association of CYP1B1 Leu432Val polymorphism and lung cancer risk: an updated meta-analysis.

Authors:  Xianjun Lao; Xue Qin; Qiliu Peng; Zhiping Chen; Yu Lu; Yanqiong Liu; Shan Li
Journal:  Lung       Date:  2014-07-03       Impact factor: 2.584

5.  CYP1B1 C4326G polymorphism and susceptibility to cervical cancer in Chinese Han women.

Authors:  Ya Li; Shi-Qiao Tan; Qian-Hong Ma; Lei Li; Zhong-Ying Huang; Yan Wang; Shang-Wei Li
Journal:  Tumour Biol       Date:  2013-06-23

6.  CYP1B1 Leu432Val polymorphism and colorectal cancer risk among Caucasians: a meta-analysis.

Authors:  Yong Xie; Guo-Qing Liu; Xiong-Ying Miao; Yi Liu; Wei Zhou; De-Wu Zhong
Journal:  Tumour Biol       Date:  2011-12-22

7.  Hormone-related pathways and risk of breast cancer subtypes in African American women.

Authors:  Stephen A Haddad; Kathryn L Lunetta; Edward A Ruiz-Narváez; Jeannette T Bensen; Chi-Chen Hong; Lara E Sucheston-Campbell; Song Yao; Elisa V Bandera; Lynn Rosenberg; Christopher A Haiman; Melissa A Troester; Christine B Ambrosone; Julie R Palmer
Journal:  Breast Cancer Res Treat       Date:  2015-10-12       Impact factor: 4.872

8.  Association of genetic variants of xenobiotic and estrogen metabolism pathway (CYP1A1 and CYP1B1) with gallbladder cancer susceptibility.

Authors:  Kiran Lata Sharma; Akash Agarwal; Sanjeev Misra; Ashok Kumar; Vijay Kumar; Balraj Mittal
Journal:  Tumour Biol       Date:  2014-02-18

Review 9.  Lung cancer in women: an overview with special focus on Spanish women.

Authors:  J Remon; E Molina-Montes; M Majem; P Lianes; D Isla; P Garrido; E Felip; N Viñolas; J de Castro; A Artal; M-J Sánchez
Journal:  Clin Transl Oncol       Date:  2013-11-26       Impact factor: 3.405

10.  Gastrointestinal stromal tumors, somatic mutations and candidate genetic risk variants.

Authors:  Katie M O'Brien; Irene Orlow; Cristina R Antonescu; Karla Ballman; Linda McCall; Ronald DeMatteo; Lawrence S Engel
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.